This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Hypertension and risk of development of type 2 diabetes

Authoring team

Nazarzadeh et al performed a one-stage individual participant data meta-analysis, in which data were pooled to investigate the effect of blood pressure lowering per se on the risk of new-onset type 2 diabetes (1)

Results:

  • analysis (n=145,939) found reduction of systolic blood pressure by 5 mmHg overall reduced risk of type 2 diabetes (HR 0.89; 95% CI 0.84-0.95)

  • ACE inhibitors and angiotensin II receptor blockers reduced risk but use of beta-blockers and thiazides increased risk

Conclusions:

  • blood pressure lowering is an effective strategy for the prevention of new-onset type 2 diabetes
    • established pharmacological interventions, however, have qualitatively and quantitively different effects on diabetes, likely due to their differing off-target effects, with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers having the most favourable outcomes
    • evidence supports the indication for selected classes of antihypertensive drugs for the prevention of diabetes, which could further refine the selection of drug choice according to an individual's clinical risk of diabetes

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.